The FDA expanded Bristol Myers Squibb’s CAR‑T therapy Breyanzi to include third‑line marginal zone lymphoma, making it the first CAR‑T approved for this slow‑growing non‑Hodgkin lymphoma subtype. The label expansion provides an option for patients with relapsed disease after prior therapies and broadens commercial indications for Breyanzi. Regulatory documents cited trial data supporting efficacy in this population and will affect treatment sequencing and reimbursement discussions. Clarification: Marginal zone lymphoma (MZL) is an indolent B‑cell lymphoma where targeted systemic therapies and watchful waiting are common prior treatments.